- Case-Based Roundtable
- General Dermatology
- Eczema
- Chronic Hand Eczema
- Chronic Spontaneous Urticaria
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
- Buy-and-Bill
Article
NICE recommends adalimumab as treatment for plaque psoriasis
National report - The National Institute for Health and Clinical Excellence (NICE) is recommending adalimumab as a treatment for adults with plaque psoriasis, redOrbit reports.
National report
- The National Institute for Health and Clinical Excellence (NICE) is recommending adalimumab as a treatment for adults with plaque psoriasis, redOrbit reports.
NICE is recommending the drug for those whom anti-tumor necrosis factor treatment is being considered and when the following criteria are both met: The disease is severe as defined by a total Psoriasis Area Severity Index of 10 or more and a Dermatology Life Quality Index of more than 10, and when the psoriasis has not responded to standard systemic therapies or if the person is intolerant of or has a contraindication to these treatments.
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
